Skip to content
Screener

Ultragenyx Pharmaceutical RARE Financing Cash Flow

Financing Cash Flow at other companies

Eli Lilly logo
Eli LillyLLY
$8.43B+777%
Amgen logo
AmgenAMGN
-$1.48B+44.6%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
-$412.29M-33,163%
Arrowhead Research logo
Arrowhead ResearchARWR
$795.72M+761%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
-$52.8M-3,386%
Regenxbio logo
RegenxbioRGNX
$17.57M-87.4%

Other financials

Income statement

See full
Revenue$214.0M+28.1%
Operating income-$75.0M+30.6%
Net income-$92.0M+20.0%
EPS (diluted)-$0.90+23.1%

Balance sheet

See full
Cash & equivalents$125.0M-29.0%
Total debt$36.0M-10.8%
Total equity-$291.0M-293%
Total assets$1.3B-3.2%

Cash flow

See full
Operating cash flow-$97.0M+11.0%
CapEx$1.0M-66.7%
Free cash flow-$98.0M+12.5%

Valuation

See full
Market cap$2.46B-9.2%
P/S3.4×-1.0×

Profitability

See full
Gross margin97.2%
Operating margin-73.6%-7.3pp
Net margin-81.7%-4.9pp
FCF margin-68.2%-1.7pp

Returns & leverage

See full
Return on equity-325.6%+36.9pp
Debt / equity3.7×
Current ratio1.7×-0.7×

Where this comes from

Reported directly by Ultragenyx Pharmaceutical in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The source filing: Ultragenyx Pharmaceutical’s 10-K, filed February 18, 2026.

Filed
Feb 18, 2026, 4:59 PM EST
Fiscal year
FY2025
Accession
0001193125-26-057329
Line itemYear Ended December 31, 2025Year Ended December 31, 2024Year Ended December 31, 2023
Proceeds from the issuance of common stock under equity plans, net6118
Proceeds from issuance of equity from noncontrolling interest7
Other1
Net cash provided by financing activities478399388
Effect of exchange rate changes on cash4(2)
Net increase (decrease) in cash, cash equivalents, and restricted cash252(35)81
Cash, cash equivalents, and restricted cash at beginning of year184219138
Cash, cash equivalents, and restricted cash at end of year$436$184$219

Item 16. Form 10-K Summary

FAQ

What is Ultragenyx Pharmaceutical's financing cash flow?
Ultragenyx Pharmaceutical (RARE) reported financing cash flow of $394.19M in Q4 2025.
How has Ultragenyx Pharmaceutical's financing cash flow changed year-over-year?
Ultragenyx Pharmaceutical's financing cash flow increased by 13285.1% year-over-year, from $2.95M to $394.19M.
What is the long-term trend for Ultragenyx Pharmaceutical's financing cash flow?
Over 4 years (2021 to 2025), Ultragenyx Pharmaceutical's financing cash flow has grown at a 41.7% compound annual growth rate (CAGR), from $118.55M to $478.19M.
What does financing cash flow mean?
Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.

Ask your AI about Ultragenyx Pharmaceutical's financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude